FDA Approves BUPRENORPHINE AND NALOXONE — Ascend Laboratories, LLC

On June 15, 2021, Ascend Laboratories, LLC received FDA approval for its Abbreviated New Drug Application #214930, introducing a generic version of Buprenorphine and Naloxone in the sublingual route. This approval expands the availability of this critical medication, providing significant competition in the buprenorphine/naloxone market.